While
exacerbation of cardiac inflammation is in fact a major concern for
T. cruzi vaccine development, as there are fears that an increased
immune response could lead to an increased autoimmunity and
tissue damage [7], our data indicate that DNA vaccination was safe
and effective for T. cruzi control. Nonetheless, further evaluation of
the therapeutic vaccine needs to be performed, particularly when
administered during the chronic phase of the disease, which is
when it would be most useful for veterinary use.